Navigation Links
BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
Date:10/24/2007

SAN FRANCISCO, Oct. 24 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced data demonstrating that BSI-401 inhibited pancreatic cancer cell growth in vitro and in vivo, both alone and in combination with oxaliplatin. BSI-401 is BiPar's second-generation product in a new class of cancer therapies known as PARP (poly-ADP-ribose polymerase) inhibitors.

Researchers presented the data at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.

"These results demonstrate the potential of BSI-401 to treat one of the most deadly and difficult-to-treat cancers," said James L. Abbruzzese, professor of gastrointestinal medical oncology and associate medical director of the gastrointestinal center at the University of Texas M.D. Anderson Cancer Center, who helped conduct the research. "Because of PARP's role in DNA repair, inhibitors of the protein may make tumors more sensitive to oxaliplatin, which induces breaks in DNA strands, and could also be powerful enough to act as a targeted monotherapy."

Pancreatic cancer kills more than 30,000 each year in the United States. Patients with advanced pancreatic cancer do not usually survive a year after diagnosis, and the limited therapeutic options have made improved treatments a major unmet need in oncology.

In animals with orthotopic human pancreatic tumors, BSI-401 administered significantly reduced tumor burden and extended survival. In addition, a synergistic effect was seen with BSI-401 in combination with oxaliplatin.

PARP is a well-characterized and validated target for cancer therapies. PARP-1 plays a central role in cell proliferation in DNA repair, and the PARP-1 gene is upregulated in certain tumor types.

BiPar's novel, proprietary PARP inhibit
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... DUBLIN , May 05, 2015 Research ... announced the addition of the "Chromatography (Instruments ... report to their offering. Chromatography ... and identifying the component of a complex mixture ... Over the decades the scientists have considered chromatography ...
(Date:5/6/2015)... May 6, 2015   CEFALY Technology , the ... device specifically authorized for use prior to the onset ... in migraine treatment at the EUROHEADPAIN - Midterm Meeting ... Valencia, Spain , from May 14-17, 2015. ... of EUROHEADPAIN, a major European research project focused on ...
(Date:5/6/2015)... Advanced wound care - assess products, developments, ... future hold for the advanced wound care ... potential revenues to 2025, assessing data, trends, opportunities and ... provides 115 tables, charts, and graphs covering 12 distinct ... industry and the future market prospects. You will see ...
Breaking Medicine Technology:Global Chromatography (Instruments and Reagents) Market 2015 - Forecasts to 2019 2CEFALY to Present Breakthrough Data in Migraine Treatment at International Headache Society Congress 2Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 2Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 3Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 4Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 5Advanced Wound Care Market Forecast 2015-2025: Prospects for Leading Companies in Wound Care Biologics, Moist Wound Care and Wound Care Devices 6
... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... exchange up to $180,000,000 in aggregate principal amount of outstanding ... like principal amount of new 2.875% Series 2012 Convertible Senior ... name of the New Notes has been amended from the ...
... Pa., Jan. 3, 2012  The board of directors of Kensey ... the board has declared a cash dividend of $0.25 ... stockholders of record on January 31, 2012.  The dividend will ... initial dividend under a new policy whereby the board of ...
Cached Medicine Technology:PDL BioPharma Announces Expiration and Preliminary Results of its Exchange Offer 2Kensey Nash Corporation Adopts Cash Dividend Policy; Declares Initial Quarterly Dividend of $0.25 per Share 2Kensey Nash Corporation Adopts Cash Dividend Policy; Declares Initial Quarterly Dividend of $0.25 per Share 3Kensey Nash Corporation Adopts Cash Dividend Policy; Declares Initial Quarterly Dividend of $0.25 per Share 4
(Date:5/6/2015)... May 06, 2015 The Beryl Institute ... of Patient Experience Journal (PXJ), an international, open ... around understanding and improving patient experience. The second volume ... experience conversation globally, helps align the voices engaged and ... , Published in association with The Beryl Institute, Volume ...
(Date:5/6/2015)... 06, 2015 Is Colorado’s legal cannabis ... month the Centennial State will mark the 18-month milestone ... to adults. And while Colorado’s legal marijuana industry has ... time, it’s also facing some new challenges. , For ... facing shortages, especially in the wake of last month’s ...
(Date:5/6/2015)... vcfo, a specialized consulting firm that provides access ... optimize business performance and productivity, announced the additions of ... Both Lynch and Scheaffer have more than 25 years ... are delighted to add Jack and Mike to the ... in financial management and leadership, Mike and Jack will ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
(Date:5/6/2015)... 2015 Locally owned, Greek olive oil producer ... past week as having one the best Extra Virgin Olive ... the Peloponnese region of Greece and known as Laconiko ... category of Medium Olive Oil, which is defined by the ... With over 700 producer applicants from 25 different countries applying, ...
Breaking Medicine News(10 mins):Health News:Patient Experience Journal Releases Spring 2015 Issue 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2
... non-invasive way to determine the existence and extent of ... pharmacologic strategies to combat the condition. These findings are ... by John Wiley & Sons on behalf of the ... The article is also available online at Wiley Interscience ...
... Dr. Yukai He wants to put cancer in the bulls eye. ... Cancer Center immunologist says of the scary reality that cancer cells ... doesnt always see cancer as a horrific invader. , Tumors and ... main player in anti-tumor immunity, cohabitate for many years before the ...
... disability in the United States. Over the next 25 ... toll of this disease will escalate. To have a ... on our nations health care and public health systems, estimating ... arthritisis critical. , The National Arthritis Data Workgroup was formed ...
... R. Bloomberg, Health Commissioner Dr. Thomas R. Frieden, and Consumer ... 2007 New York City Youth Risk Behavior Survey (YRBS) showing ... 20 percent between 2005 and 2007. The citys teen smoking ... six years, from 17.6 percent in 2001 to 8.5 percent ...
... in red wine grapes may significantly reduce the ability ... published recently in the Journal of Agricultural and Food ... large amounts in fermented seeds and skins cast away ... bacteria to contribute to tooth decay. Beyond cavities, the ...
... of Medicine (BUSM) have found that vitamin D2 is equally ... The study appears online in the December 2007 issue ... studied healthy adults aged 18-84 who received either placebo, 1,000 ... D2, or 500 IU of vitamin D2 plus 500 IU ...
Cached Medicine News:Health News:MRI techniques evolving towards better assessment of liver fibrosis 2Health News:New strategies work to put cancer on the firing line 2Health News:New strategies work to put cancer on the firing line 3Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 2Health News:The prevalence and impact of arthritis and other rheumatic conditions in the United States 3Health News:Smoking rate among New York City teens was lowest on record in 2007 2Health News:Smoking rate among New York City teens was lowest on record in 2007 3Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 2Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 3Health News:Winemaking waste proves effective against disease-causing bacteria in early studies 4Health News:Vitamin D2 is as effective as vitamin D3 in maintaining concentrations of 25-hydroxyvitamin D 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: